Our Thesis: Adial Pharmaceuticals Inc., is the only company to genetically cater to Alcohol Use Disorder (AUD), a large and relatively untapped market. Adial’s lead drug, AD04, has demonstrated efficacy and safety in the initial trials and promises to treat AUD without the need for abstinence and with no withdrawal effects. We believe that if AD04 is approved, it could generate total revenue approaching $1 billion in a relatively short span of time and post-high bottom-line. The company will enjoy reaping benefits for a longer period given that it has well-protected sets of patents to maintain its value proposition in the marketplace at least until 2032. The company is also developing drugs in the pain-relieving space which could add more to their value.
07 Apr 2021
Adial Pharmaceuticals Inc. Initiating Coverage
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Adial Pharmaceuticals Inc. Initiating Coverage
- Published:
07 Apr 2021 -
Author:
Karl Egeland -
Pages:
26
Our Thesis: Adial Pharmaceuticals Inc., is the only company to genetically cater to Alcohol Use Disorder (AUD), a large and relatively untapped market. Adial’s lead drug, AD04, has demonstrated efficacy and safety in the initial trials and promises to treat AUD without the need for abstinence and with no withdrawal effects. We believe that if AD04 is approved, it could generate total revenue approaching $1 billion in a relatively short span of time and post-high bottom-line. The company will enjoy reaping benefits for a longer period given that it has well-protected sets of patents to maintain its value proposition in the marketplace at least until 2032. The company is also developing drugs in the pain-relieving space which could add more to their value.